Kittai A - Search Results

1

Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.

Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV. Gordon MJ, et al. Among authors: kittai a. Cancer. 2018 Aug 1;124(15):3192-3200. doi: 10.1002/cncr.31554. Epub 2018 May 24. Cancer. 2018. PMID: 29797667 Free article.

2

Glabellar and auricular leukemia cutis in CLL.

Steinman B, Plaza JA, Kittai AS. Steinman B, et al. Among authors: kittai as. EJHaem. 2022 Aug 28;3(4):1398-1399. doi: 10.1002/jha2.538. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467811 Free PMC article. No abstract available.

3

Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.

Best S, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A, Danilov AV. Best S, et al. Among authors: kittai a. Blood Adv. 2019 Jan 8;3(1):51-62. doi: 10.1182/bloodadvances.2018026880. Blood Adv. 2019. PMID: 30617217 Free PMC article.

4

Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.

Kittai AS, Lunning M, Danilov AV. Kittai AS, et al. Curr Hematol Malig Rep. 2019 Aug;14(4):302-309. doi: 10.1007/s11899-019-00511-1. Curr Hematol Malig Rep. 2019. PMID: 31049852 Review.

5

Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.

Best S, Liu T, Bruss N, Kittai A, Berger A, Danilov AV. Best S, et al. Among authors: kittai a. Leuk Lymphoma. 2019 Dec;60(12):2946-2950. doi: 10.1080/10428194.2019.1616190. Epub 2019 May 21. Leuk Lymphoma. 2019. PMID: 31111763

6

Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.

Kittai AS, Woyach JA. Kittai AS, et al. Cancer J. 2019 Nov/Dec;25(6):428-435. doi: 10.1097/PPO.0000000000000406. Cancer J. 2019. PMID: 31764124

7

Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.

Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova OV, Murray S, Berger A, Pennock ND, Lind EF, Danilov AV. Best S, et al. Among authors: kittai a. Leukemia. 2021 Jan;35(1):156-168. doi: 10.1038/s41375-020-0794-0. Epub 2020 Mar 16. Leukemia. 2021. PMID: 32203139 Free PMC article.

8

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.

Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV. Kittai AS, et al. Transplant Cell Ther. 2021 Jan;27(1):46-52. doi: 10.1016/j.bbmt.2020.09.028. Epub 2020 Sep 29. Transplant Cell Ther. 2021. PMID: 33002640 Free article.

9

A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.

Raghunathan V, Fan G, Kittai AS, Okada C, Danilov AV, Spurgeon SE. Raghunathan V, et al. Eur J Haematol. 2021 Feb;106(2):294-297. doi: 10.1111/ejh.13538. Epub 2020 Nov 2. Eur J Haematol. 2021. PMID: 33089525

10

A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.

Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X, Dmitrovsky E. Kawakami M, et al. Mol Cancer Ther. 2021 Mar;20(3):477-489. doi: 10.1158/1535-7163.MCT-19-0987. Epub 2020 Dec 4. Mol Cancer Ther. 2021. PMID: 33277443 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page